Literature DB >> 23441755

Low prostaglandin E2 and cyclooxygenase expression in nasal mucosa fibroblasts of aspirin-intolerant asthmatics.

Jordi Roca-Ferrer1, Maria Pérez-Gonzalez, Francesc J Garcia-Garcia, Javier Pereda, Laura Pujols, Isam Alobid, Joaquim Mullol, Cesar Picado.   

Abstract

BACKGROUND AND
OBJECTIVE: Anomalies in the regulation of cyclooxygenase (COX)-1 and -2 have been described in nasal polyps of aspirin-induced asthma (AIA). Whether these anomalies are specific to nasal polyps or affect all the nasal mucosa (NM) of upper airways is still unclear. The objective of this study was to compare the COX pathway in NM of AIA patients with the NM of control subjects.
METHODS: Fibroblasts were isolated from NM of five AIA patients (AIA-NM) and five control subjects (control-NM). Cells were treated with 10 ng/mL interleukin (IL)-1β for up to 72 h. Prostaglandin E2 (PGE2 ) production was measured by enzyme-linked immunosorbent assay (ELISA), expression of COX-1 protein by Western blot and COX-2 protein by ELISA, Western blot and immunofluorescence techniques.
RESULTS: IL-1β increased PGE2 production and COX-1 protein expression in control-NM fibroblasts, but no changes were found in AIA-NM. IL-1β provoked a significant time-dependent increase in COX-2 protein expression in control-NM fibroblasts but had a very mild effect on COX-2 protein expression in AIA-NM.
CONCLUSIONS: Our data suggest that abnormalities in the COX pathway are not a phenomenon exclusive to nasal-polyp mucosa as they are also present in all the NM of AIA patients. These anomalies may be involved in the pathogenesis of airway inflammation and non-steroidal anti-inflammatory drug intolerance in asthma patients with chronic rhinosinusitis and nasal polyposis.
© 2013 The Authors. Respirology © 2013 Asian Pacific Society of Respirology.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23441755     DOI: 10.1111/resp.12076

Source DB:  PubMed          Journal:  Respirology        ISSN: 1323-7799            Impact factor:   6.424


  10 in total

1.  Aspirin desensitization: useful treatment for chronic rhinosinusitis with nasal polyps (CRSwNP) in aspirin-exacerbated respiratory disease (AERD)?

Authors:  Ludger Klimek; Ralph Dollner; Oliver Pfaar; Joaquim Mullol
Journal:  Curr Allergy Asthma Rep       Date:  2014-06       Impact factor: 4.806

Review 2.  Aspirin sensitivity: Lessons in the regulation (and dysregulation) of mast cell function.

Authors:  Joshua A Boyce
Journal:  J Allergy Clin Immunol       Date:  2019-10       Impact factor: 10.793

Review 3.  Hypersensitivity to Aspirin and other NSAIDs: Diagnostic Approach in Patients with Chronic Rhinosinusitis.

Authors:  Joanna Makowska; Anna Lewandowska-Polak; Marek L Kowalski
Journal:  Curr Allergy Asthma Rep       Date:  2015-08       Impact factor: 4.806

4.  Release of cyclooxygenase-2 and lipoxin A4 from blood leukocytes in aspirin-exacerbated respiratory disease.

Authors:  Ajnacska Rozsasi; Akos Heinemann; Tilman Keck
Journal:  Allergy Rhinol (Providence)       Date:  2016-01-01

5.  In Vitro and In Vivo Validation of EP2-Receptor Agonism to Selectively Achieve Inhibition of Mast Cell Activity.

Authors:  Judith Plaza; Rosa Torres; Adrián Urbano; César Picado; Fernando de Mora
Journal:  Allergy Asthma Immunol Res       Date:  2020-07       Impact factor: 5.764

6.  Lung function and side effects of Aspirin desensitization: a real world study.

Authors:  Turpeinen Heikki; Laulajainen-Hongisto Anu; Lyly Annina; Numminen Jura; Penttilä Elina; Johanna Sahlman; Toppila-Salmi Sanna; Kauppi Paula
Journal:  Eur Clin Respir J       Date:  2021-01-11

Review 7.  Immune-Mediated Mechanisms in Cofactor-Dependent Food Allergy and Anaphylaxis: Effect of Cofactors in Basophils and Mast Cells.

Authors:  Rosa Muñoz-Cano; Clara San Bartolome; Rocío Casas-Saucedo; Giovanna Araujo; Sonia Gelis; Maria Ruano-Zaragoza; Jordi Roca-Ferrer; Francis Palomares; Margarita Martin; Joan Bartra; Mariona Pascal
Journal:  Front Immunol       Date:  2021-02-17       Impact factor: 7.561

Review 8.  Monoclonal Antibodies and Airway Diseases.

Authors:  Annina Lyly; Anu Laulajainen-Hongisto; Philippe Gevaert; Paula Kauppi; Sanna Toppila-Salmi
Journal:  Int J Mol Sci       Date:  2020-12-13       Impact factor: 5.923

Review 9.  The Nose as a Route for Therapy: Part 1. Pharmacotherapy.

Authors:  Cemal Cingi; Nuray Bayar Muluk; Dimitrios I Mitsias; Nikolaos G Papadopoulos; Ludger Klimek; Anu Laulajainen-Hongisto; Maija Hytönen; Sanna Katriina Toppila-Salmi; Glenis Kathleen Scadding
Journal:  Front Allergy       Date:  2021-02-22

10.  Prostaglandin E2 Induces IL-6 and IL-8 Production by the EP Receptors/Akt/NF-κB Pathways in Nasal Polyp-Derived Fibroblasts.

Authors:  Jung-Sun Cho; In-Hye Han; Hye Rim Lee; Heung-Man Lee
Journal:  Allergy Asthma Immunol Res       Date:  2014-06-04       Impact factor: 5.764

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.